Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Celgene Corporation : to Webcast at Upcoming Investor Conferences and Analyst Day

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/29/2013 | 02:40pm CET

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences in May. The conferences will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com. Celgene management will provide an overview of the Company.

Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock Conference at 1:20 p.m. ET.

Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.

Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global Healthcare Conference at 11:30 a.m. ET.

Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's 29th Annual Strategic Decisions Conference at 9:00 a.m. ET.

Additionally, Celgene plans to host an Analyst and Institutional Investor Day on May 6. The presentation will be webcast beginning at 1 p.m. ET and is expected to conclude at 5 p.m.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Celgene Corporation
Jacqualyn A. Fouse, Ph.D., 908-673-9956
EVP, Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
03/23 ONCOLYTICS BIOTECH : reg; Inc. Enters into First-in-Class Collaboration with Mye..
03/22 Cigna Named i4cp's Member of the Year
03/22 CELGENE : House Oversight and Government Reform Subcommittee on Health Care, Ben..
03/16 CELGENE : Oral OTEZLA® Apremilast Demonstrated Significant Improvement versus Pl..
03/15 ALLIQUA BIOMEDICAL, INC. (NASDAQ : ALQA) Files An 8-K Entry into a Material Defi..
03/14 AGIOS PHARMACEUTICALS : Announces MTAP Pathway Research Program as Development P..
03/14 CELGENE : embraces MTAP cancer deal with fast-moving collaborator Agios
03/13 AGIOS PHARMACEUTICALS, INC. (NASDAQ : AGIO) Files An 8-K Other Events
03/11 CELGENE : Regenacy Pharmaceuticals Demonstrates Reversal Of Chemotherapy-Induced..
03/09 Genentech & Bristol-Myers Squibb Dominate Franchise Image, Overall Engagement..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/22 Best Price-Positioned Integrated Oil & Gas Stocks, As Seen By Market-Makers
03/20 Corporate Venture Capital - Savior Of Medtech?
03/20 Novo Nordisk - Another Apple 2013 Story? New Highs Ahead?
03/17 AMGEN TANKS ON REPATHA DATA : Analysis
03/16 CELGENE : In Breakout Mode?
Advertisement
Financials ($)
Sales 2017 13 286 M
EBIT 2017 7 280 M
Net income 2017 4 542 M
Debt 2017 3 113 M
Yield 2017 -
P/E ratio 2017 22,00
P/E ratio 2018 17,66
EV / Sales 2017 7,45x
EV / Sales 2018 6,28x
Capitalization 95 861 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 141 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION6.45%95 861
AMGEN, INC.13.56%122 281
GILEAD SCIENCES, INC.-5.75%88 214
REGENERON PHARMACEUTIC..-0.56%38 722
ACTELION LTD24.72%29 697
VERTEX PHARMACEUTICALS..20.88%22 123
More Results